← Back to Clinical Trials
Recruiting NCT07436247

NCT07436247 Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07436247
Status Recruiting
Phase
Sponsor Prim. Prof. Dr. Oliver Findl, MBA
Condition Cataract
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2024-04-04
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 110 Years
Study Type OBSERVATIONAL
Interventions
Osiris-T Pyramid Wavefront Sensor - (CSO, Italy)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2024-04-04 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To correlate ocular morphology from anterior segment OCT and pyramid wavefront sensing in order to comprehensively analyze pseudophakic in vivo image quality of presbyopia-correcting IOLs in cataract patients.

Eligibility Criteria

Inclusion Criteria: 1. Men and women aged above 21 years with prior uncomplicated cataract/IOL exchange surgery 2. Willing to sign informed consent before measurements 3. Corrected distance visual acuity (CDVA) of 0.1 logMAR or better 4. Absence of corneal scars/dry eye disease that could falsify the light transmission of the study eye 5. Total absence of posterior capsule opacification or patients who already have undergone Nd:YAG capsulotomy 6. Absence of ocular comorbidity (Macular degeneration, glaucoma, amblyopia) Exclusion Criteria: 1. Prior corneal refractive or ocular surgery 2. Posterior capsule opacification. 3. Keratometry between \<42.5 and \>45 D, 4. Corneal spherical aberration \> 0.4 microns 5) Angle kappa \> 0.4 mm 6\) Zonular weakness 7) Pseudoexfoliation syndrome 8) Eccentric fixation or insufficient ability to fixate (tremor, nystagmus) 9) Pregnancy

Contact & Investigator

Central Contact

Stefan Georgiev, MD, PhD

✉ office@viros.at

📞 +43 1 91021

Principal Investigator

Oliver Findl, Prof., Dr.

PRINCIPAL INVESTIGATOR

Vienna Institute for Research in Ocular Surgery

Frequently Asked Questions

Who can join the NCT07436247 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 110 Years, studying Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07436247 currently recruiting?

Yes, NCT07436247 is actively recruiting participants. Contact the research team at office@viros.at for enrollment information.

Where is the NCT07436247 trial being conducted?

This trial is being conducted at Vienna, Austria, Vienna, Austria.

Who is sponsoring the NCT07436247 clinical trial?

NCT07436247 is sponsored by Prim. Prof. Dr. Oliver Findl, MBA. The principal investigator is Oliver Findl, Prof., Dr. at Vienna Institute for Research in Ocular Surgery. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology